Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 7/20 | 0.34 |
| ▸ | PPARG | P37231 | 6/20 | 0.34 |
| ▸ | PRF1 | P14222 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12535500 | 0.92 | ADORA1 (0.43) | ADORA1SLC6A3HRH3FFAR1PPARA | |
| SCHEMBL12536119 | 0.91 | ADORA1 (0.38) | ADORA1SLC6A3HRH3FFAR1PPARA | |
| SCHEMBL383022 | 0.90 | ADORA1 (0.46) | ADORA1SLC6A3HRH3FFAR1PPARA | |
| SCHEMBL12535546 | 0.89 | ADORA1 (0.37) | ADORA1SLC6A3HRH3FFAR1PPARA | |
| SCHEMBL12535550 | 0.88 | ADORA1 (0.38) | ADORA1SLC6A3HRH3FFAR1PPARA | |
| SCHEMBL382471 | 0.85 | ADORA1 (0.51) | ADORA1SLC6A3PPARGPRF1HSD17B10 | |
| SCHEMBL12535119 | 0.85 | ADORA1 (0.53) | ADORA1SLC6A3PPARGHSD17B10MAPT | |
| SCHEMBL12910853 | 0.85 | PPARA (0.39) | ADORA1SLC6A3FFAR1PPARAPPARG | |
| SCHEMBL1933429 | 0.84 | ADORA1 (0.43) | ADORA1SLC6A3FFAR1PPARAPPARG | |
| SCHEMBL12535499 | 0.84 | ADORA1 (0.35) | ADORA1SLC6A3FFAR1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9095582-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-8440700-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20110130377-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110003845-A1 | SUBSTITUTED AZABICYCLIC COMPOUNDS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003845-A1 | SUBSTITUTED AZABICYCLIC COMPOUNDS AND THE USE THEREOF | PPIP5K2, TPMT, PNPO | ADORA1 2110/4885SLC6A3 3269/4885HRH3 3234/4885 |
| US-20110130377-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | AADAC, CYP4X1, AGXT | ADORA1 3589/4885SLC6A3 2005/4885HRH3 3099/4885 |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | CYP4X1, AHR, AGXT | ADORA1 2450/4885SLC6A3 2093/4885HRH3 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.